PTC Therapeutics | PTCT - Debt


PTC Therapeutics reported $286.94M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Amgen USD 54.6B 17M Dec/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 6.56B 275.1M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Cytokinetics USD 1.29B 4.48M Mar/2026
Daiichi Sankyo JPY 201.14B 99.81B Sep/2025
Enanta Pharmaceuticals USD 1.35M 0 Dec/2024
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Gilead Sciences USD 24.94B 5M Dec/2025
Incyte USD 39.43M 982K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Novartis USD 47B 11.62B Mar/2026
Pfizer USD 63.73B 231M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
TG Therapeutics USD 253.71M 8.37M Dec/2025
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026
Xencor USD 187.75M 118.48M Dec/2025